Form 4: Kezar Life Sciences Director Acquires Stock Options

Director Graham K. Cooper acquired stock options in Kezar Life Sciences, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Graham K. Cooper, a director of Kezar Life Sciences, Inc., acquired stock options.
• The options grant the right to buy 50,000 shares of Kezar Life Sciences common stock at an exercise price of $0.67 per share.
• The options vest 100% on June 20, 2025, contingent upon Cooper's continued service to the company.
• The options expire on June 19, 2034.
• Following the transaction, Cooper beneficially owns 50,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) which is generally viewed positively as it aligns director interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in biotech companies like Kezar Life Sciences.
• The vesting schedule of one year is fairly typical, incentivizing continued service and commitment to the company's long-term success.
• Comparable companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates